Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

Regulatory

June 19, 2024

Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency

Read more

June 3, 2024

Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency

Read more

Regulatory

May 6, 2024

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024

Read more

Upcoming event

June 20, 2024, 8.00am CEST

Webcast about Triac Trial II results

Latest presentation

June 20, 2024

Replay of Triac Trial II topline results webcast

Latest Report

May 3, 2024

Interim report Q1 2024

Calendar and upcoming reports

August 22, 2024

Interim Report Q2 2024 (7:00am CEST)

September 19, 2024

Pareto Annual Healthcare Conference

November 8, 2024

Interim Report Q3 2024 (7:00am CET)

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all